Eltrombopag – an Oral Thrombopoietin Agonist

Total Page:16

File Type:pdf, Size:1020Kb

Eltrombopag – an Oral Thrombopoietin Agonist European Review for Medical and Pharmacological Sciences 2012; 16: 743-746 Eltrombopag – an oral thrombopoietin agonist V. SHARMA, H. RANDHAWA, A. SHARMA, S. AGGARWAL Department of Medicine, University College of Medical Sciences, New Delhi (India) Abstract. – The therapy for immune of the thrombocytopenia. The two major throm- thrombocytopenic purpura (ITP) has evolved in bopoietin agonists which have a role in the man- the recent past. In certain cases therapy for ITP agement of the thrombocytopenia, especially the remains inadequate. Thrombopoietin receptor agonists are the latest addition to the armamen- immune thrombocytopenic purpura (ITP), in- 2 tarium to manage the thrombocytopenia. While clude romiplostim and eltrombopag . Romi- romiplostim was the first second generation plostim is a peptibody administered as once a thrombopoietin agonist to become available, el- week subcutaneous injection in non-responding trombopag is particularly attractive as it is an or relapsing ITP. Eltrombopag is a non peptide orally bioavailable agent. This review focuses on thrombopoietin agonist which has also been the use, safety and efficacy of eltrombopag in various clinical conditions. found to be efficacious in similar conditions. The fact that it is orally bioavailable makes eltrom- Key Words: bopag a more attractive option. Thrombopoietin agonists, Eltrombopag, Immune Chemistry and Structure thrombocytopenic purpura. Eltrombopag, a non-peptide synthetic throm- bopoietin receptor agonist, is a biaryl hydrazone with a molecular weight of 564.6 Dalton. Mechanism of Action Introduction Thrombopoietin, a cytokine produced in the liver, acts on the thrombopoietin receptors Thrombocytopenia (platelet count <100.000/μL) (TPO-R) which are present on the megakary- can accompany a multitude of conditions including ocytes. Thrombopoietin binds to these receptors disorders of marrow (aplastic anaemia, myelodys- and activates the Janus kinase (JAK 2) and tyro- plasias, lymphomas and leukemias), enhanced sine kinase 2 pathways. This results in the activa- immune mediated platelet destruction (Immune tion of signal transducers and activators of tran- thrombocytopenia, drug induced, secondary to scription five (STAT 5), phosphoinositide-3 ki- chronic lymphatic leukemia (CLL), etc), dissem- nase and ras-mitogen activated protein kinase inated intravascular coagulation, thrombotic (MAPK)3-5. The net result is the differentiation of thrombocytopenic purpura, septicaemia, hyper- the bone marrow precursor cells along the splenism, etc. Therapies to treat thrombocytope- megakaryocytic lineage. Thrombopoietin has an nia are still evolving and management of threat- antiapoptotic effect and stimulates megakary- ening thrombocytopenia, in resistant cases, re- ocyte maturation. Eltrombopag, in association mains inadequate. Thrombopoietin and its recep- with metal ions (Zn2+) activates the TPO-R. tors are one of the major targets of newer thera- Since the interaction between eltrombopag and pies aimed at increasing platelet counts. While endogenous thrombopoietin on the TPO-R is first generation thrombopoietin analogues in non-competitive, their effects are additive6. form of recombinant human thrombopoietin had efficacy in increasing platelet levels initially, de- Dosage and Administration velopment of alloantibodies against these ana- The FDA approved eltrombopag in November logues compromised their efficacy on a contin- 2008 for use in immune thrombocytopenic purpu- ued therapy1. ra (ITP) patients who had failed at least one prior Second generation thrombopoietin agonists therapy such as corticosteroids, immunoglobulins have emerged as a new hope in the management or splenectomy. Eltrombopag has been used in Corresponding Author: Vishal Sharma, MD; e-mail: [email protected] 743 V. Sharma, H. Randhawa, A. Sharma, S. Aggarwal dose of 25, 30, 50 and 75 mg daily for various du- Table I. Indications for use of Eltrombopag. rations in trials in patients of chronic ITP. Al- though the maximum increase in platelet levels is Approved indication seen with a dose of 75 mg, a dose of 50 mg each Immune thrombocytopenic purpura day achieves acceptable increase in platelet counts Under evaluation with a fewer side effects7. As already mentioned, Chemotherapy-induced thrombocytopenia. Hepatitis C related thrombocytopenia the drug is taken orally. If the response is inade- Thrombocytopenia due to marrow abnormalities or quate the dosage can be increased to a maximum hematologic malignancy of 75 mg. One should aim to increase the platelet Chronic liver disease related thrombocytopenia count to more than 50,000/μL, to prevent bleeding manifestations. However, normalisation of the platelets is not the goal of therapy. The drug is study reported no difference in frequency or best taken 2 hours prior to or after a meal and 6 severity of adverse effects of eltrombopag vis-a- hours after the ingestion of antacids, calcium and vis placebo. The study also demonstrated throm- vitamin supplements to achieve a predictable ab- bopoietic efficacy in normal male subjects. How- sorption and attain consistent plasma levels. A ever, lower doses (5, 10 and 20 mg) showed no randomised control trial conducted by Williams et difference in platelet counts from placebo. Bussel al[8] indicated that the concomitant administration et al[7] studied the effect of eltrombopag in adult of eltrombopag with antacids containing magne- patients with chronic ITP who had relapses or sium, aluminium or with calcium rich food re- were refractory to standard therapy. A dose de- duced its bioavailability. pendent response in form of increasing platelet counts was seen with the dose of 30, 50 and 75 Pharmacokinetics mg. In 80% of the patients the response was evi- Around 50% of the drug is absorbed after the dent within 15 days of initiation of therapy. The oral intake, and peak plasma levels are obtained safety of this drug was reconfirmed in this trial. 2-6 hours after the oral dose. Plasma elimination half-life is 21 to 32 hours. Absorption is inter- Cirrhosis due to Hepatitis C fered by concurrent aluminium and high fat Chronic hepatitis C virus infection results in au- meals, as already mentioned. The drug is highly toimmune thrombocytopenia which appears well protein bound. Eltrombopag is extensively me- before the liver failure has set in. Once cirrhosis tabolized by oxidation via that CYP 1A2 and develops, a decreased production of thrombopoi- 2C8 and is then glucuronidated. elimination oc- etin from the liver further decreases the platelet curs via both faeces and urine9. count. McHutchinson et al[10] observed a positive effect of eltrombopag on the platelet counts in pa- Indications tients with thrombocytopenia due to HCV related As of today eltrombopag is approved by US cirrhosis. The increase in platelet counts was help- FDA for use in ITP only. However, emerging ful in the completion of the antiviral therapy in a data has alluded to the role of this agent in man- significant number of patients. Dose escalation to aging thrombocytopenia associated with other 75 mg has been shown to increase the platelet etiologies. In patients with hepatitis C related counts in cases of ITP that did not respond to a cirrhosis eltrombopag has been shown to in- lower dose, i.e. 50 mg13. crease the platelet counts to above 100.000/μL, thereby, enabling the use of peg-interferon ther- Ongoing Eesearch apy. Use of eltrombopag resulted in a signifi- Trials are currently underway to explore the cant number of initially thrombocytopenic pa- role of eltrombopag in conditions like myelodys- tients achieving completion of antiviral thera- plastic syndrome, secondary acute myeloid py10. The indications for use of eltrombopag are leukemia after myelodysplastic syndrome, pa- mentioned in Table I11. tients of sarcoma receiving adriamycin and ifos- famide, aplastic anemia patients with immuno- Immune Thrombocytopenic Purpura (ITP) suppressive-therapy, refractory thrombocytope- A phase 1 placebo controlled trial to assess the nia and Wiskott-Aldrich syndrome. Trials are al- safety of various doses (5, 10, 25, 30, 50, 75 mg) so on to find if eltrombopag can reduce the need given over a period of ten days was conducted in for platelet transfusions in patients of chronic liv- healthy male subjects by Jenkins et al12. The er disease who undergo elective procedures. 744 Eltrombopag – an oral thrombopoietin agonist Table II. Important trials of Eltrombopag. References Patient subset Dosage Results Bussel et al 2007 (7) Placebo controlled 30 mg, 50 mg, Platelets > 50,000 RCT 118 chronic ITP 75 mg for 42 days was achieved in 28% Platelets <30,000/μL, (30 mg), 70% Relapsing or refractory ITP (50 mg) and 81% (75 mg) patients in three groups respectively Jenkins et al 2007 (12) 73 placebo controlled 5, 10, 25, 30, 50, No difference in adverse healthy adults 75 mg for 10 days effects between placebo and active drug Mchutchinson et al 2007 (10) Placebo controlled 30, 50, 75 mg for Platelets > i lakh/μL were RCT 74 HCV related 4 weeks achived in 75% (30 mg), cirrhotic patients with 79 (50 mg) and 95% platelets between (75 mg) 20-70.000/μL Bussel et al 2009 (13) Placebo controlled Dose of 50 mg for 59% pts on eltrombopag RCT in chronic ITP 3 wks, increased to 50 mg achieved platelet 75 mg in nonresponders count ≥50.000. Amongst nonresponders 29% dose escalation Contraindications regularly monitored. Bone marrow reticulin de- There are no known contraindications to the position is seen with the prolonged therapy. Bone use of eltrombopag.
Recommended publications
  • How I Treat Myelofibrosis
    From www.bloodjournal.org by guest on October 7, 2014. For personal use only. Prepublished online September 16, 2014; doi:10.1182/blood-2014-07-575373 How I treat myelofibrosis Francisco Cervantes Information about reproducing this article in parts or in its entirety may be found online at: http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests Information about ordering reprints may be found online at: http://www.bloodjournal.org/site/misc/rights.xhtml#reprints Information about subscriptions and ASH membership may be found online at: http://www.bloodjournal.org/site/subscriptions/index.xhtml Advance online articles have been peer reviewed and accepted for publication but have not yet appeared in the paper journal (edited, typeset versions may be posted when available prior to final publication). Advance online articles are citable and establish publication priority; they are indexed by PubMed from initial publication. Citations to Advance online articles must include digital object identifier (DOIs) and date of initial publication. Blood (print ISSN 0006-4971, online ISSN 1528-0020), is published weekly by the American Society of Hematology, 2021 L St, NW, Suite 900, Washington DC 20036. Copyright 2011 by The American Society of Hematology; all rights reserved. From www.bloodjournal.org by guest on October 7, 2014. For personal use only. Blood First Edition Paper, prepublished online September 16, 2014; DOI 10.1182/blood-2014-07-575373 How I treat myelofibrosis By Francisco Cervantes, MD, PhD, Hematology Department, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain Correspondence: Francisco Cervantes, MD, Hematology Department, Hospital Clínic, Villarroel 170, 08036 Barcelona, Spain. Phone: +34 932275428.
    [Show full text]
  • Thrombopoietin Supports the Continuous Growth of Cytokine-Dependent Human Leukemia Cell Lines HG Drexler, M Zaborski and H Quentmeier
    Leukemia (1997) 11, 541–551 1997 Stockton Press All rights reserved 0887-6924/97 $12.00 Thrombopoietin supports the continuous growth of cytokine-dependent human leukemia cell lines HG Drexler, M Zaborski and H Quentmeier DSMZ-German Collection of Microorganisms and Cell Cultures, Department of Human and Animal Cell Cultures, Mascheroder Weg 1 B, D-38124 Braunschweig, Germany Hematopoiesis is a complex process of regulated cellular pro- nate membrane receptor. This binding triggers a series of intra- liferation and differentiation from the primitive stem cells to the cellular mediators involved in the growth factor’s signaling final fully differentiated cell. The long and extensive search for a factor specifically regulating megakaryocytopoiesis led to the pathways. Recently, a novel hematopoietic growth factor, cloning of a hormone, here called thrombopoietin (TPO), that termed thrombopoietin (TPO), was cloned and shown to be a specifically promotes proliferation and differentiation of the megakaryocytic lineage-associated growth and differentiation megakaryocytic lineage. The availability of recombinant TPO factor. Binding of TPO to its receptor, c-MPL, mediates plei- and its imminent clinical use has made a more detailed under- otropic effects on megakaryocyte development in vitro and in standing of its effects on hematopoietic cells more urgent. Nor- vivo. TPO is clearly the primary regulator of this cell lineage mal megakaryocyto- and thrombopoiesis occurs predomi- nantly in the bone marrow, a difficult organ to study in situ, acting at all levels of megakaryocytopoiesis and thrombopo- particularly in humans, due to the low numbers of megakary- iesis (reviewed in Ref. 1). ocytic progenitors and the consequent difficult isolation as The availability of TPO will be of considerable clinical pure populations.
    [Show full text]
  • Side Effects of Molecular-Targeted Therapies in Solid Cancers : a New Challenge in Cancer Therapy Management
    Side effects of molecular-targeted therapies in solid cancers : a new challenge in cancer therapy management Ahmad Awada, MD, PhD Medical Oncology Clinic Institut Jules Bordet Université Libre de Bruxelles (U.L.B.) Brussels, Belgium PLAN OF THE LECTURE 1. Concept 2. Achievements on the management of side effects 3. Remaining challenges 4. New challenges with the development of molecular-targeted therapies 5. Conclusions Reducing the cancer- related problems and the side effects of the SUPPORTIVE CARE = medicine administered to treat the disease SIDE EFFECTS OF CANCER THERAPY: ACHIEVEMENTS Side effect Preventive & Therapeutic intervention • Febrile neutropenia • G-CSF, Anti-infectives • Anemia • Epoetine •Mucositis •Laser therapy, Palifermin • Nausea & Vomiting • 5-HT3 and neurokin-1-receptor antagonists •Thromboembolic •LMW Heparin events • Cardiomyopathy • Liposomal formulations, Dexrazonane (anthracyclines) MANAGEMENT OF SIDE EFFECTS : REMAINING CHALLENGES • Alopecia • Thrombocytopenia ( ! Promising Thrombopoietin- mimetics are under investigation) • Asthenia MOLECULAR TARGETS AND THERAPIES (1) Drug Class Mechanism of action Main tumor indication Gefitinib* Small molecule TK inhibitor of EGFR NSCLC (Iressa) Erlotinib* Small molecule TK inhibitor of EGFR NSCLC (Tarceva) Cetuximab* Monoclonal Antibody Blocks EGFR Colorectal, Head & (Erbitux) Neck, NSCLC Monoclonal Panitumumab* Antibody Blocks EGFR Colorectal (Vectibix) * Investigational in BC TK : tyrosine kinase; EGFR : epidermal growth factor receptor MOLECULAR TARGETS AND THERAPIES
    [Show full text]
  • DOPTELET (Avatrombopag) RATIONALE for INCLUSION IN
    DOPTELET (avatrombopag) RATIONALE FOR INCLUSION IN PA PROGRAM Background Doptelet is a thrombopoietin (TPO) receptor agonist used to increase platelet counts. Doptelet (avatrombopag) is an orally bioavailable, small molecule TPO receptor agonist that stimulates proliferation and differentiation of megakaryocytes from bone marrow progenitor cells resulting in an increased production of platelets. Doptelet does not compete with TPO for binding to the TPO receptor and has an additive effect with TPO on platelet production (1). Regulatory Status FDA approved indication: Doptelet is a thrombopoietin receptor agonist indicated for the treatment of: (1) 1. Thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure. 2. Thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. Doptelet should not be administered to patients with chronic liver disease in an attempt to normalize platelet counts (1). Doptelet is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic and thromboembolic complications in patients with chronic liver disease. A Doppler ultrasound is a noninvasive test that can be used to estimate the blood flow through blood vessels by bouncing high-frequency sound waves (ultrasound) off circulating red blood cells. A Doppler ultrasound may help determine if Doptelet therapy is appropriate for a patient (1-2). The safety and effectiveness of Doptelet in pediatric patients have not been established (1). Summary Doptelet is a thrombopoietin (TPO) receptor agonist used to increase platelet counts. Doptelet (avatrombopag) is an orally bioavailable, small molecule TPO receptor agonist that stimulates proliferation and differentiation of megakaryocytes from bone marrow progenitor cells resulting in an increased production of platelets.
    [Show full text]
  • Insights Into the Cellular Mechanisms of Erythropoietin-Thrombopoietin Synergy
    Papayannopoulou et al.: Epo and Tpo Synergy Experimental Hematology 24:660-669 (19961 661 @ 1996 International Society for Experimental Hematology Rapid Communication ulation with fluorescence microscopy. Purified subsets were grown in plasma clot and methylcellulose clonal cultures and in suspension cultures using the combinations of cytokines Insights into the cellular mechanisms cadaveric bone marrow cells obtained from Northwest described in the text. Single cells from the different subsets Center, Puget Sound Blood Bank (Seattle, WA), were were. also deposited (by FACS) on 96-well plates containing of erythropoietin-thrombopoietin synergy washed, and incubated overnight in IMDM with 10% medmm and cytokines. Clonal growth from single-cell wells calf serum on tissue culture plates to remove adherent were double-labeled with antiglycophorin A-PE and anti­ Thalia Papayannopoulou, Martha Brice, Denise Farrer, Kenneth Kaushansky From the nonadherent cells, CD34+ cells were isolated CD41- FITC between days 10 and 19. direct immunoadherence on anti-CD34 monoclonal anti­ University of Washington, Department of Medicine, Seattle, WA (mAb)-coated plates, as previously described [15]. Purity Immunocytochemistry Offprint requests to: Thalia Papayannopoulou, MD, DrSci, University of Washington, isolated CD34+ cells ranged from 80 to 96% by this For immunocytochemistry, either plasma clot or cytospin cell Division of Hematology, Box 357710, Seattle, WA 98195-7710 od. Peripheral blood CD34 + cells from granulocyte preparations were used. These were fixed at days 6-7 and (Received 24 January 1996; revised 14 February 1996; accepted 16 February 1996) ulating factor (G-CSF)-mobilized normal donors 12-13 with pH 6.5 Histochoice (Amresco, Solon, OH) and provided by Dr.
    [Show full text]
  • The Molecular Mechanisms That Control Thrombopoiesis
    The molecular mechanisms that control thrombopoiesis Kenneth Kaushansky J Clin Invest. 2005;115(12):3339-3347. https://doi.org/10.1172/JCI26674. Review Series Our understanding of thrombopoiesis — the formation of blood platelets — has improved greatly in the last decade, with the cloning and characterization of thrombopoietin, the primary regulator of this process. Thrombopoietin affects nearly all aspects of platelet production, from self-renewal and expansion of HSCs, through stimulation of the proliferation of megakaryocyte progenitor cells, to support of the maturation of these cells into platelet-producing cells. The molecular and cellular mechanisms through which thrombopoietin affects platelet production provide new insights into the interplay between intrinsic and extrinsic influences on hematopoiesis and highlight new opportunities to translate basic biology into clinical advances. Find the latest version: https://jci.me/26674/pdf Review series The molecular mechanisms that control thrombopoiesis Kenneth Kaushansky Department of Medicine, Division of Hematology/Oncology, University of California, San Diego, San Diego, California, USA. Our understanding of thrombopoiesis — the formation of blood platelets — has improved greatly in the last decade, with the cloning and characterization of thrombopoietin, the primary regulator of this process. Thrombopoietin affects nearly all aspects of platelet production, from self-renewal and expansion of HSCs, through stimulation of the proliferation of megakaryocyte progenitor cells, to support of the maturation of these cells into platelet-pro- ducing cells. The molecular and cellular mechanisms through which thrombopoietin affects platelet production provide new insights into the interplay between intrinsic and extrinsic influences on hematopoiesis and highlight new opportunities to translate basic biology into clinical advances.
    [Show full text]
  • Cytokine Signaling in Tumor Progression
    Immune Netw. 2017 Aug;17(4):214-227 https://doi.org/10.4110/in.2017.17.4.214 pISSN 1598-2629·eISSN 2092-6685 Review Article Cytokine Signaling in Tumor Progression Myungmi Lee, Inmoo Rhee* Department of Bioscience and Biotechnology, Sejong University, Seoul 05006, Korea Received: Apr 13, 2017 ABSTRACT Revised: Jun 22, 2017 Accepted: Jun 25, 2017 Cytokines are molecules that play critical roles in the regulation of a wide range of normal *Correspondence to functions leading to cellular proliferation, differentiation and survival, as well as in Inmoo Rhee specialized cellular functions enabling host resistance to pathogens. Cytokines released Department of Bioscience and Biotechnology, in response to infection, inflammation or immunity can also inhibit cancer development Sejong University, 209 Neungdong-ro, and progression. The predominant intracellular signaling pathway triggered by cytokines Gwangjin-gu, Seoul 05006, Korea. is the JAK-signal transducer and activator of transcription (STAT) pathway. Knockout mice Tel: +82-2-6935-2432 E-mail: [email protected] and clinical human studies have provided evidence that JAK-STAT proteins regulate the immune system, and maintain immune tolerance and tumor surveillance. Moreover, aberrant Copyright © 2017. The Korean Association of activation of the JAK-STAT pathways plays an undeniable pathogenic role in several types Immunologists of human cancers. Thus, in combination, these observations indicate that the JAK-STAT This is an Open Access article distributed under the terms of the Creative Commons proteins are promising targets for cancer therapy in humans. The data supporting this view Attribution Non-Commercial License (https:// are reviewed herein. creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial Keywords: Cytokine; JAK-STAT; Cancer; Kinase inhibitor use, distribution, and reproduction in any medium, provided the original work is properly cited.
    [Show full text]
  • The Thrombopoietin Receptor : Revisiting the Master Regulator of Platelet Production
    This is a repository copy of The thrombopoietin receptor : revisiting the master regulator of platelet production. White Rose Research Online URL for this paper: https://eprints.whiterose.ac.uk/175234/ Version: Published Version Article: Hitchcock, Ian S orcid.org/0000-0001-7170-6703, Hafer, Maximillian, Sangkhae, Veena et al. (1 more author) (2021) The thrombopoietin receptor : revisiting the master regulator of platelet production. Platelets. pp. 1-9. ISSN 0953-7104 https://doi.org/10.1080/09537104.2021.1925102 Reuse This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here: https://creativecommons.org/licenses/ Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ Platelets ISSN: (Print) (Online) Journal homepage: https://www.tandfonline.com/loi/iplt20 The thrombopoietin receptor: revisiting the master regulator of platelet production Ian S. Hitchcock, Maximillian Hafer, Veena Sangkhae & Julie A. Tucker To cite this article: Ian S. Hitchcock, Maximillian Hafer, Veena Sangkhae & Julie A. Tucker (2021): The thrombopoietin receptor: revisiting the master regulator of platelet production, Platelets, DOI: 10.1080/09537104.2021.1925102 To link to this article: https://doi.org/10.1080/09537104.2021.1925102 © 2021 The Author(s).
    [Show full text]
  • All Requests for Thrombopoietin (TPO) Receptor Agonists Require a Prior
    Updated: 03/2020 DMMA Approved: 04/2020 Request for Prior Authorization for Thrombopoietin (TPO) Receptor Agonists Website Form – www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158 All requests for Thrombopoietin (TPO) Receptor Agonists require a Prior Authorization and will be screened for medical necessity and appropriateness using the criteria listed below. Thrombopoietin (TPO) Receptor Agonists Prior Authorization Criteria: Thrombopoietin (TPO) Receptor Agonists include Doptelet, Mulpleta, Nplate, and Promacta. New products with this classification will require the same documentation. For all requests for Thrombopoietin (TPO) Receptor Agonists all of the following criteria must be met: For non-preferred agents, the member has had a trial and failure of a preferred agent or a clinically submitted reason for not having a trial of a preferred agent The requested dose and frequency is in accordance with FDA-approved labeling, nationally recognized compendia, and/or evidence-based practice guidelines Examples of products and corresponding FDA-approved indications: Indication Product Chronic Immune Thrombocytopenia (ITP) Doptelet, Nplate, Promacta Thrombocytopenia in adults with CLD who are scheduled Doptelet, Mulpleta to undergo a procedure Thrombocytopenia in adults with hepatitis C to allow Promacta initiation and maintenance of interferon-based therapy Aplastic anemia Promacta Coverage may be provided with a diagnosis of chronic immune thrombocytopenia (ITP) and the following criteria is met: For Nplate and Promacta,
    [Show full text]
  • (ITP)—Focus on Thrombopoietin Receptor Agonists
    21 Review Article Page 1 of 21 The treatment of immune thrombocytopenia (ITP)—focus on thrombopoietin receptor agonists David J. Kuter Hematology Division, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA Correspondence to: Professor David J. Kuter, MD, DPhil. Hematology Division, Massachusetts General Hospital, Ste. 118, Room 110, Zero Emerson Place, Boston, MA 02114, USA. Email: [email protected]. Abstract: Immune thrombocytopenia (ITP) is an autoimmune disease characterized by increased platelet destruction along with reduced platelet production. All treatments attempt either to reduce the rate of platelet production or increase the rate of platelet production. There is no known cure but most patients attain a hemostatic platelet count. New treatment guidelines have supported a shift from corticosteroids and splenectomy to newer medical treatments that mitigate the thrombocytopenia and avoid splenectomy. The thrombopoietin receptor agonists (TPO-RA), romiplostim, eltrombopag, and avatrombopag, have markedly altered the treatment of ITP. Response rates of 80–90% are routinely obtained and responses are usually maintained with continued therapy. Data shows that TPO-RA are just as effective in early ITP as in chronic ITP and current guidelines encourage their use as early as 3 months into the disease course, sometimes even earlier. TPO-RA do not need to be continued forever; about a third of patients in the first year and about another third after two years have a remission. Whether TPO-RA affect the ITP pathophysiology and directly cause remission remains unclear. This review provides a personal overview of the diagnosis and treatment of ITP with a focus on the mechanism of action of TPO-RA, their place in the treatment algorithm, unique aspects of their clinical use, adverse effects, and options should they fail.
    [Show full text]
  • Investigating Reptin Function in Acute Myeloid Leukaemia
    INVESTIGATING REPTIN FUNCTION IN ACUTE MYELOID LEUKAEMIA Elena Armenteros Monterroso Developmental Biology and Cancer Section Institute of Child Health University College London A thesis submitted for the Degree of Doctor of Philosophy 2017 DECLARATION I, Elena Armenteros Monterroso, confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis. Signature …………………………………….. 2 ACKNOWLEDGEMENTS Firstly, I would like to express my sincere gratitude to my principal supervisor, Dr. Owen Williams, for his excellent advice, support and motivation during the past 4 years. I am extremely grateful for his guidance, but also for the freedom he has given me to pursue my own research. I could not have imagined having a better supervisor. I would also like to extend my gratitude to my second supervisor, Dr. Jasper de Boer. His help and advice have been invaluable. But also the fun environment he has provided in the lab, which made it easier to carry on during stressful times. I am also thankful to all the inspirational people working at the Cancer Section, particularly all the members of my lab, for their help and friendship during the past years. My sincere thanks also goes to all the members of the UCL Genomics team for their efficient work and their help with my sequencing experiments. I am also truly thankful to all my friends, both in the UK and in Spain, for providing the enthusiasm and support that I needed during my studies. I would like to specially thank Miriam, Clare and Heike for their friendship and fun times together.
    [Show full text]
  • Clinical Hypothyroidism in a Renal Cell Carcinoma Patient Treated with Sorafenib
    H&0 CLINICAL CASE STUDIES Clinical Hypothyroidism in a Renal Cell Carcinoma Patient Treated With Sorafenib Matthew S. Block, MD, PhD Department of Oncology, Division of Medical Oncology, Manish Kohli, MD Mayo Clinic, Rochester, Minnesota Case Presentation laboratory reference, range 8–48 U/L) and alanine trans- aminase (maximum 92 U/L; laboratory reference range, A 54-year-old man presented to a local emergency room 7–55 U/L), with no detectable abnormalities in alka- with gross hematuria. A computed tomography (CT) line phosphatase or bilirubin. Abdominal ultrasound scan of the abdomen revealed a left renal mass. He under- showed no evidence of hepatic or renal involvement of went a left radical nephrectomy; pathology showed a renal cell carcinoma and no evidence of renal outflow 7.9 × 6.5 × 6.3–cm, grade 2 (out of 4) renal cell carci- obstruction. Urinalysis showed no proteinuria and no noma, clear cell type. The tumor was confined to the evidence of glomerulonephritis or nephrotic syndrome. kidney, but tumor thrombus was present in the renal vein A serum thyroid-stimulating hormone (TSH) level (stage III, T3aN0M0). Serial follow-up was performed was measured at 87.7 mIU/L (Table 1). Free thyroxine postoperatively with no clinical evidence of disease pro- was less than 0.2 ng/dL (laboratory reference range, gression until 3 years later, when a 2.3-cm right hilar 0.8–1.8 ng/dL), which, along with his presenting symp- nodule and a 0.7-cm left lower lobe nodule were detected toms of unexplained fatigue, confirmed the diagnosis of on imaging with no other clinical evidence of disease.
    [Show full text]